Itamar Medical EBIT per Share
Delisted
The EBIT per Share of Itamar Medical (ITMR.TA) as of Aug 21, 2026 is -0.02 USD. In the previous year, EBIT per Share was -0.01 USD — a change of 69.24% (lower).
Get this data via API
Financial Data API
EBIT per Share
-0.02USD
YoY
69.24%
Last updated:
EBIT per Share of Itamar Medical is 2026 -0.02 USD. EBIT per Share of Itamar Medical was 2025 -0.01 USD. It decreases by 69.24% lower compared to the previous year.
Access this data via the Eulerpool API
Itamar Medical Stock analysis
What does Itamar Medical do? Itamar Medical Ltd is a company specialized in the development and marketing of non-invasive diagnostic and monitoring solutions for sleep disorders, heart diseases, and peripheral vascular diseases. The company was founded in Israel in 1997.
The history of Itamar Medical begins with the development of the PAT system (Peripheral Arterial Tone), a device that uses the peripheral arterial tonometer to measure blood flow. With this system, doctors were able to record patients' sleep for the first time and diagnose sleep disorders such as obstructive sleep apnea syndrome (OSAS) or restless leg syndrome (RLS).
Over the years, the company has expanded its offerings and developed various solutions to improve the diagnosis and monitoring of heart and vascular diseases. Itamar Medical's products now include the EndoPAT, WatchPAT, and Total Sleep Solution, among others.
The EndoPAT is a non-invasive medical device that measures the endothelial function state of patients. This refers to the ability of blood vessels to dilate when needed to increase blood flow. The EndoPAT allows doctors to assess the cardiovascular health status of patients and predict the risk of cardiovascular diseases.
The WatchPAT is a wearable sleep monitor that wirelessly connects to an app. The device records the sleep architecture of patients and automatically detects sleep apnea episodes, which are then displayed on the app. The WatchPAT enables doctors to improve the sleep quality of patients and diagnose sleep disorders.
Itamar Medical's Total Sleep Solution offers a comprehensive solution for the management of sleep disorders. The solution includes the WatchPAT tracker, the PAT procedures for sleep disorder diagnosis, and the EndoPAT procedures for assessing cardiovascular health. This combination of technologies allows doctors to treat their patients holistically and improve their cardiovascular health and sleep quality.
Itamar Medical has also formed partnerships with other companies to enhance its solutions and promote new developments. Currently, the company is collaborating with Teva Pharmaceutical Industries to develop a new formulation of Sildenafil, a medication used for treating erectile dysfunction.
Overall, Itamar Medical has experienced strong growth in recent years. The company has branches in the USA, Europe, and Asia and is constantly working to expand its offerings and improve its technology for the diagnosis and monitoring of heart and sleep disorders.
In summary, Itamar Medical is an innovative provider of non-invasive diagnostic and monitoring solutions for sleep disorders, heart diseases, and peripheral vascular diseases. With its wide range of products and partnerships with other companies, the company is well-positioned to continue growing and expanding in the coming years. Itamar Medical is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Itamar Medical stock
EBIT per Share of Itamar Medical is -0.02 USD in 2026.
EBIT per Share of Itamar Medical changed from -0.01 USD to -0.02 USD, representing a 69.24% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Itamar Medical since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Itamar Medical
All Key Metrics — Itamar Medical
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth